<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00923910</url>
  </required_header>
  <id_info>
    <org_study_id>080051</org_study_id>
    <secondary_id>08-C-0051</secondary_id>
    <nct_id>NCT00923910</nct_id>
    <nct_alias>NCT00608166</nct_alias>
  </id_info>
  <brief_title>Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood</brief_title>
  <official_title>A Pilot Trial of WT1 Peptide-Loaded Allogeneic Dendritic Cell Vaccine and Donor Lymphocyte Infusion for WT1-Expressing Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

        -  Most patients with acute lymphoblastic leukemia (ALL) and many patients with acute
           myelogenous leukemia (AML), chronic myelogenous leukemia (CML) and non-Hodgkin's
           lymphoma (NHL) have a protein called Wilm's Tumor 1 (WT1) in their cancer cells. This
           protein is thought to be able to influence the growth of these cancers.

        -  A vaccine made with the WT1 protein may boost the immune system to help fight these
           cancers in patients whose cancer cells contain the protein.

      Objectives:

        -  To determine the safety, effectiveness and side effects of giving the WT1 vaccine and
           donor white blood cells to patients with AML, ALL, CML or NHL who have previously
           received standard treatment and undergone stem cell transplantation.

        -  To determine the immune response to the WT1 vaccine and donor white blood cells in these
           patients and to determine if the response is related to the amount of WT1 protein in the
           patient's cancer cells.

      Eligibility:

        -  Patients between 1 and 75 years of age with the blood antigen human leukocyte antigen
           (HLA-A2) and the WT1 cancer protein who have persistent or recurrent blood cancers after
           stem cell transplantation.

        -  The prior stem cell transplant donor must be willing to provide additional cells, which
           will be used to prepare the cellular vaccines and for donor lymphocyte (white blood
           cell) infusions.

      Design:

        -  Patients are given the WT1 vaccine every 2 weeks for 6 weeks (weeks 0, 2, 4, 6, 8, 10).
           Each vaccination consists of two injections in the upper arm or thigh.

        -  On weeks 0, 4 and 8, patients also receive white blood cells from a donor to enhance the
           immune response. The cells are also given as a 15- to 30-minute infusion through a vein
           about 1 hour after the vaccine injection. Donor infusions are given only to patients
           with mild or no graft-vs-host disease resulting from their prior stem cell
           transplantation.

        -  Periodic physical examinations, blood and urine tests, scans to evaluate disease and
           other tests as needed are done for 12 months after enrollment in the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

        -  Efforts to incorporate anti-tumor immunotherapy at stages of minimal residual disease
           (MRD) burden are limited by profound host immune depletion associated with standard
           anti-cancer therapies.

        -  Allogeneic blood and marrow stem cell transplantation (SCT) can be curative for a number
           of hematologic malignancies. Part of the success of this approach is an allogeneic
           immunologic reaction that has been demonstrated to play a role in the eradication of
           residual malignant disease after transplant in certain cancers (the so called
           graft-versus-leukemia, GVL, or graft-versus-tumor, GVT, effect). Nonetheless, relapse
           remains the primary cause of treatment failure after allogeneic SCT.

        -  The Wilm's tumor 1 (WT1) gene product is a tumor-associated antigen that represents a
           potential target for immunotherapy in a wide array of cancers. WT1 is expressed in most
           cases of acute leukemia and in many cases of chronic myelogenous leukemia and
           myelodysplastic syndromes. Importantly, WT1 has limited expression in normal tissues
           beyond embryogenesis. This trial represents an attempt to incorporate antigen-specific
           immunotherapy in the setting of allogeneic adoptive cell transfer.

      Objectives:

        -  To determine the safety, toxicity, and feasibility of donor-derived dendritic cell
           vaccination and donor lymphocyte infusion (DLI) after allogeneic SCT.

        -  To determine the frequency and severity of graft-vs.-host disease (GVHD) in patients
           treated with peptide-loaded donor-derived dendritic cell vaccination and donor
           lymphocyte infusion (DLI).

        -  To evaluate whether immunologic responses to WT1-specific peptides can be generated by
           peptide-loaded donor-derived dendritic cell vaccination and DLI after allogeneic SCT.

        -  To evaluate whether clinical responses to WT1-specific peptides can be generated by
           peptide-loaded donor-derived dendritic cell vaccination and DLI after allogeneic SCT.

        -  To evaluate whether immunologic and/or clinical responses may be associated with the
           degree of WT1 expression by malignant cells or pre-existing donor anti-WT1 immunity.

      Eligibility:

        -  HLA-A2 plus patients may be enrolled on this trial if they have relapsed or residual
           disease following allogeneic SCT for a WT1 expressing hematologic malignancy.

        -  Donors from the previous SCT, related or unrelated, must be 5- or 6- antigen genotypic
           HLA-matched (single HLA-A or B locus mismatch allowed) and HLAA2 plus.

      Design:

        -  This is a pilot study, the primary aim of which is to assess safety and feasibility of
           this novel vaccine strategy aimed to enhance the GVL effect after allogeneic SCT.

        -  Donor-derived dendritic cells prepared from peripheral blood monocytes will be loaded
           with a combination of three WT1-derived peptides. These peptides are each comprised of
           one WT1-derived oligomeric epitope known to bind to HLA-A2 and an 11-mer protein
           transduction epitope known to enhance peptide loading and antigen presentation.

        -  Patients will receive donor-derived dendritic cell vaccines every 14 days for 6 doses.
           Donor leukocyte infusions (DLI) will also be administered with the vaccine.

        -  Study endpoints will include toxicity, feasibility, antigen-specific immunity, and
           disease response.

        -  This is an exploratory pilot trial. Up to 12 patients will be treated.

        -  Stopping rules will take effect if excessive toxicity (e.g., GVHD) or inability to
           generate vaccines are observed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 22, 2008</start_date>
  <completion_date type="Actual">November 15, 2016</completion_date>
  <primary_completion_date type="Actual">October 18, 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity</measure>
    <time_frame>21 months</time_frame>
    <description>Here is the number of participants with adverse events. For details of the adverse events, see the adverse event module.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Graft Versus Host Disease (GVHD) Greater Than or Equal to Grade 3</measure>
    <time_frame>28 days following completion of last vaccine and/or DLI (donor lymphocyte infusion) administration</time_frame>
    <description>Acute Graft versus Host Disease (GVHD) was graded by the modified Glucksberg scale. 0 = no GVHD normal, 4 = severe GVHD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Immune Response</measure>
    <time_frame>4 to 12 weeks</time_frame>
    <description>Immune response was monitored by use of interferon gamma Enzyme-Linked Immunospot (ELISpot) and by delayed-type hypersensitivity (DTH) testing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wilm's Tumor 1 (WT1) Enzyme-Linked Immunospot (ELISpot)</measure>
    <time_frame>48 to 72 hours after placement</time_frame>
    <description>WT1 expression of the hematologic malignancy was confirmed by either having greater than 15% of malignant cells react with anti-WT1 by immunohistochemistry or by having a positive quantitative reverse transcription polymerase chain reaction (RT-PCR) of WT1 compared with a negative control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wilm's Tumor (WT1) Delayed-type Hypersensitivity (DTH)</measure>
    <time_frame>48 to 72 hours after placement</time_frame>
    <description>WT1 expression of the hematologic malignancy was confirmed by either having greater than 15% of malignant cells react with anti-WT1 by immunohistochemistry or by having a positive quantitative reverse transcription polymerase chain reaction (RT-PCR) of WT1 compared with a negative control. DTH skin testing was performed using KLH and with a cocktail of WT1 peptides as 2 separate injections. Enzyme-Linked Immunospot (ELISpot) was performed against each peptide and was considered positive if results were at least 10 spots above background on at least 2 measurements. DTH was considered positive if there was at least .5cm induration 48 to 72 hours after placement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Keyhole Limpet Hemocyanin (KLH) Delayed-type Hypersensitivity (DTH)</measure>
    <time_frame>48 to 72 hours after placement</time_frame>
    <description>KLH is a neoantigen known to induce helper response was used concurrently as a vaccine adjuvant and control antigen. DTH skin testing was performed using KLH and with a cocktail of WT1 peptides as 2 separate injections. Enzyme-Linked Immunospot (ELISpot) was performed against each peptide and was considered positive if results were at least 10 spots above background on at least 2 measurements. DTH was considered positive if there was at least .5cm induration 48 to 72 hours after placement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Progressive Disease</measure>
    <time_frame>4 to12 weeks</time_frame>
    <description>Progressive disease is at least a 20% increase in the sum of the longest diameter of all target lesions (i.e. tumor response). Response criteria for acute leukemia's is worse marrow classification (i.e., M status) with at least a 50% increase in the percentage of marrow blasts, or no change in marrow classification (i.e., M status), but a 50% or greater increase in absolute peripheral blast count or extent of medullary disease</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Leukemia, Acute Myelogenous (AML)</condition>
  <condition>Leukemia, Acute Lymphocytic (ALL)</condition>
  <condition>Leukemia, Chronic Myelogenous (CML)</condition>
  <condition>Myelodysplastic Syndrome (MDS)</condition>
  <condition>Non-Hodgkin's Lymphoma (NHL)</condition>
  <arm_group>
    <arm_group_label>Donors</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Related and unrelated donors undergo lymphapheresis to prepare cellular vaccines and to donate lymphocytes for infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Recipients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive donor lymphocytes and vaccines prepared from donors.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WT1 Peptide-Pulsed Dendritic Cells</intervention_name>
    <arm_group_label>Recipients</arm_group_label>
    <other_name>Wilm's Tumor 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donor Lymphocytes</intervention_name>
    <description>Lymphocytes from donors (related or unrelated) collected via lymphapheresis.</description>
    <arm_group_label>Donors</arm_group_label>
    <arm_group_label>Recipients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IL-4</intervention_name>
    <description>water-soluble protein; this study will use GMCSF (granulocyte macrophage colony stimulating factor)/IL-4 generated monocyte derived dendritic cells</description>
    <arm_group_label>Recipients</arm_group_label>
    <other_name>Interleukin-4</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KLH</intervention_name>
    <description>Neoantigen known to induce helper responses; will be used concurrently as a vaccine adjuvant and control antigen.</description>
    <arm_group_label>Recipients</arm_group_label>
    <other_name>keyhole limpet hemocyanin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WT1 Peptides</intervention_name>
    <description>dendritic cell vaccine</description>
    <arm_group_label>Recipients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Endotoxin</intervention_name>
    <description>Purified lipopolysaccharide prepared from E.Coli 0:113</description>
    <arm_group_label>Recipients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diphenhydramine</intervention_name>
    <description>Pre-medication</description>
    <arm_group_label>Donors</arm_group_label>
    <arm_group_label>Recipients</arm_group_label>
    <other_name>Benadryl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <description>Pre-medication</description>
    <arm_group_label>Donors</arm_group_label>
    <arm_group_label>Recipients</arm_group_label>
    <other_name>Tylenol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Inclusion Criteria: Patient (i.e., transplant recipient)

        Age greater than 1 year and less than 75 years.

        One of the following Wilm's Tumor 1 (WT1)-expressing hematologic malignancies:

          1. Acute lymphocytic leukemia (ALL), less than or equal to 25 percent marrow blasts.

          2. Acute myelogenous leukemia (AML), less than or equal to 25 percent marrow blasts.

          3. Chronic myelogenous leukemia (CML).

               -  Chronic phase, recurrent after or resistant to donor lymphocyte infusion (DLI) or
                  resistant to available abl kinase inhibitors

               -  Accelerated phase, less than 20 percent marrow blasts

               -  Blastic phase, less than or equal to 25 percent marrow blasts

          4. Myelodysplastic syndrome (MDS), less than 20 percent marrow blasts.

          5. Non-Hodgkin's lymphoma (NHL), stage 4, less than or equal to 25 percent marrow blasts.

          6. Hodgkin's lymphoma (HL)

          7. There will be no restriction on the volume of extramedullary disease, with the
             exceptions of exclusions for central nervous system involvement or progression deemed
             unacceptably rapid.

             WT1 expression will be confirmed by at least one of the following criteria:

               -  Greater than 15 percent of malignant cells react with anti-WT1 by
                  immunohistochemistry.

               -  Positive quantitative reverse transcription polymerase chain reaction (RT-PCR) of
                  WT1 compared with a negative control.

             Human leukocyte antigen (HLA-A2) plus (heterozygous expression is acceptable).

             Prior stem cell transplantation (SCT): Prior HLA-matched (5-6/6 antigen or 8-10/10
             allele) related or unrelated allogeneic SCT required. Must be at least 42 days
             post-transplant, have had recovery of transplant-associated toxicity to less than
             grade 2, and have post-transplant donor engraftment as defined by donor chimerism
             greater than 50 percent (peripheral blood), neutrophil recovery to an absolute
             neutrophil count (ANC) greater than 500/microl independent of myeloid growth factors,
             and platelet recovery to greater than 20,000/microL independent of transfusion.

             Disease status: Post-transplant residual or relapsed disease. Minimal residual disease
             (MRD) by polymerase chain reaction (PCR) or flow cytometry is acceptable in accordance
             with standard disease-specific diagnostic criteria.

             Availability of previous allogeneic donor to donate cells again.

             Prior therapy: Disease-specific therapy must be stopped at least 14 days prior to
             protocol Cycle 1 Day 1 (C1D1) and recovery of treatment-associated toxicity to greater
             than grade 2 is required prior to initiation of protocol therapy. Patients may have
             received prior DLI, but the last dose must be at least 28 days prior to C1D1 and there
             must be no active graft versus host disease (GVHD) greater than grade 1 acute or
             extensive chronic. Systemic immunosuppression must be stopped at least 28 days prior
             to protocol C1D1 and there must be no active GVHD greater than grade 1 acute or
             extensive chronic. There is no time restriction in regard to prior intrathecal
             chemotherapy provided there is complete recovery from any acute toxic effects of such.
             Patients receiving hydroxyurea are allowed.

             Performance status of 0, 1, 2, or 3.

             Renal function: Patients must have a serum creatinine less than or equal to 1.5 times
             the upper limit of normal based on age-specific normal range OR a creatinine clearance
             greater than or equal to 60 mL/min/1.73 m^2.

             Hepatic function: Patients must have a total bilirubin less than or equal to 2.0 mg/dl
             and alanine aminotransferase (ALT) less than or equal to 5 times the upper limit of
             normal based on age- specific normal ranges.

             Ability to give informed consent. For patients less than 18 years of age, their legal
             guardian must give informed consent. Pediatric patients will be included in age
             appropriate discussion in order to obtain verbal assent.

             Recipients of unrelated donor transplants must sign a release of information form to
             authorize National Marrow Donor Program (NMDP) transfer of information to the National
             Institutes of Health (NIH).

             Subjects of childbearing or child-fathering potential must be willing to use a
             medically acceptable form of birth control, which includes abstinence, while they are
             being treated on this study.

             Inclusion Criteria: Donor

             Weight greater than or equal to 18 kg, and for unrelated donors only age greater than
             or equal to 18 years

             Previous HLA-matched related or unrelated allogeneic donor. Donors must be 5-6/6
             antigen or 8-10/10 allele matched.

             HLA-A2 plus (heterozygous expression is acceptable).

             Adequate venous access for peripheral apheresis, or consent to use a temporary central
             venous catheter for apheresis.

             Donor selection will be in accordance with National Institutes of Health
             (NIH)/Clinical Center (CC) Department of Transfusion Medicine (DTM) criteria and, in
             the case of an unrelated donor, the National Marrow Donor Program (NMDP) standards.
             When a potentially eligible recipient of an unrelated donor product is identified, the
             recipient will complete an NMDP search transfer request to allow NIH NMDP staff to
             contact the NMDP Coordinating Center, who will, in turn, contact the donor's prior
             Donor Center. The NMDP Policy for Subsequent Donation Requests will be followed and
             the appropriate forms (Subsequent Donation Request form and Therapeutic T Cell
             Collection Prescription) will be submitted as required.

             Ability to give informed consent. For donors less than 18 years of age, their legal
             guardian must give informed consent. Pediatric donors must give verbal assent and be
             cleared by social work and a mental health specialist to participate.

             EXCLUSION CRITERIA:

             Exclusion Criteria: Patient

             Active graft versus host disease (GVHD) greater than grade 1 acute or extensive
             chronic.

             Breast feeding or pregnant females (due to risk to fetus or newborn).

             Central nervous system (CNS) malignancy by any of the following criteria:

               -  Demonstration of malignant cells in the cerebrospinal fluid (CSF) in patients
                  with leukemia or MDS as manifested by CSF white blood cell (WBC) greater than
                  5/microL and confirmation of CSF blasts.

               -  Cranial neuropathies deemed secondary to the underlying malignancy.

               -  CNS mass lesions deemed secondary to the underlying malignancy.

               -  Neuroblastoma (NB): History of CNS involvement without current evidence of CNS
                  malignancy is NOT an exclusion.

             Rapidly progressive malignancy and/or clinically significant systemic illness (e.g.,
             severe unstable infections or organ dysfunction) that in the judgment of the PI would
             likely compromise the patient's ability to tolerate this therapy or interfere with the
             study procedures, including but not limited to a life expectancy of less than 3
             months.

             High risk of inability to comply with protocol requirements as determined by principal
             investigator, social work, and primary team.

             Human immunodeficiency virus (HIV) infection or human T-lymphotrophic virus type 1
             (HTLV-1) infection (due to associated immune suppression and decreased likelihood of
             developing an immune response to the vaccine and increased risk of severe infection).

             Active hepatitis B or C infection as defined by seropositive for hepatitis B surface
             antigen (HbSAg) or hepatitis C and elevated liver transaminases.

             Corticosteroids (dexamethasone equivalent up to 0.1 mg/kg/day) will be permitted.
             Topical agents and/or inhaled corticosteroids are permitted.

             Exclusion Criteria: Donor

             History of medical illness that in the estimation of the principal investigator (PI)
             or Department of Transfusion Medicine (DTM)/NMDP physician poses prohibitive risk to
             donation.

             Anemia (Hb less than 10 gm/dl) or thrombocytopenia (less than 100,000/microliter).

             Breast feeding or pregnant females (due to risk to fetus or newborn).

             High risk of inability to comply with protocol requirements as determined by the
             principal investigator and donor center team.

             Positive screening test for transfusion-transmissible infection in accordance with DTM
             or NMDP donation standards.

             Kaposi's sarcoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Terry J Fry, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2008-C-0051.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Appelbaum FR. Graft versus leukemia (GVL) in the therapy of acute lymphoblastic leukemia (ALL). Leukemia. 1997 May;11 Suppl 4:S15-7. Review.</citation>
    <PMID>9179275</PMID>
  </reference>
  <reference>
    <citation>Sullivan KM, Weiden PL, Storb R, Witherspoon RP, Fefer A, Fisher L, Buckner CD, Anasetti C, Appelbaum FR, Badger C, et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood. 1989 May 1;73(6):1720-8. Erratum in: Blood 1989 Aug 15;74(3):1180.</citation>
    <PMID>2653460</PMID>
  </reference>
  <reference>
    <citation>Witz JP, Roeslin N, Avalos S, Morand G, Wihlm JM. [Benign tracheo-bronchial tumors. Other tumors]. Ann Chir. 1979 Oct;33(8):541-4. French.</citation>
    <PMID>229756</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2009</study_first_submitted>
  <study_first_submitted_qc>June 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2009</study_first_posted>
  <results_first_submitted>April 7, 2014</results_first_submitted>
  <results_first_submitted_qc>April 7, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 8, 2014</results_first_posted>
  <last_update_submitted>March 1, 2017</last_update_submitted>
  <last_update_submitted_qc>March 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institutes of Health Clinical Center (CC)</investigator_affiliation>
    <investigator_full_name>Terry Fry, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>WT1 Peptide Dendritic Cell Vaccine</keyword>
  <keyword>Hematologic Malignancies</keyword>
  <keyword>Relapse After Allogeneic Stem Cell Transplantation</keyword>
  <keyword>Donor Lymphocyte Infusions</keyword>
  <keyword>WT1-Positive</keyword>
  <keyword>Dendritic Cell Vaccine</keyword>
  <keyword>Tumor Immunotherapy</keyword>
  <keyword>Allogeneic Adoptive Immunotherapy</keyword>
  <keyword>Hodgkins Lymphoma</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Acute Myelogenous Leukemia</keyword>
  <keyword>AML</keyword>
  <keyword>Acute Lymphocytic Leukemia</keyword>
  <keyword>ALL</keyword>
  <keyword>Chronic Myelogenous Leukemia</keyword>
  <keyword>CML</keyword>
  <keyword>Myelodysplasia Syndrome</keyword>
  <keyword>Non-Hodgkin Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Keyhole-limpet hemocyanin</mesh_term>
    <mesh_term>Interleukin-4</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Promethazine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Donors</title>
          <description>Period 1 -Donor lymphocyte collection via apheresis. Period 2 -Donor cell processing for vaccine and infusion.</description>
        </group>
        <group group_id="P2">
          <title>Recipients</title>
          <description>Period 1 - Vaccine and donor lymphocyte prep Period 2 - Vaccine and donor lymphocyte administration.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Donors</title>
          <description>Donor lymphocyte collection via apheresis.</description>
        </group>
        <group group_id="B2">
          <title>Recipients</title>
          <description>Vaccine and donor lymphocyte prep</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21" spread="9.17"/>
                    <measurement group_id="B2" value="17" spread="3.71"/>
                    <measurement group_id="B3" value="19" spread="8.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease</title>
          <description>ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia.</description>
          <population>Donors were not evaluated.</population>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hodgkin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AML</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Transplantation Type</title>
          <description>NMA, nonmyeloablative; MA, myeloablative; MAx2, myeloablative conditioning. This is standard terminology in the transplant field and refers to pre-transplant chemotherapy/radiation doses that require stem cell rescue.</description>
          <population>Donors were not evaluated.</population>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>NMA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MA x 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Donors</title>
          <description>MSD, matched sibling donor; MRD*, matched related donor. MRD* was a 10/10 matched related parent for both transplantations. the first used marrow and the second used peripheral blood stem cells.; MUD, matched unrelated donor.</description>
          <population>Recipients were not evaluated.</population>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>MSD</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MRD*</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MUD</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Conditioning Regimen</title>
          <description>TBI, total body irradiation; cyclo, cyclophosphamide; etop, etoposide; HSCT, hematopoietic stem cell transplant</description>
          <population>Donors were not evaluated.</population>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Fludarabine/cyclophosphamide</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cyclophosphamide, TBI, thiotepa</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HSCT1:cyclo,TBI;HSCT2:busulfan, melphalan, etop</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cyclophosphamide, TBI</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Immunosuppression</title>
          <description>BMT, bone marrow transplant</description>
          <population>Donors were not evaluated.</population>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Cyclosporine</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sirolimus/tacrolimus, methotrexate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None after second BMT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time Off Immunosuppression before Protocol Enrollment</title>
          <population>Donors were not evaluated.</population>
          <units>Months</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Patient 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pre-Enrollment Disease Status</title>
          <population>Donors were not evaluated.</population>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>6%-8% blasts</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple 1-2cm lymph nodes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5%-10% blasts</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2% blasts</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5% blasts</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time to HCT to Relapse, mo</title>
          <population>Donors were not evaluated.</population>
          <units>Months</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Patient 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time to First Vaccine (from day 0 of HCT), mo</title>
          <population>Donors were not evaluated.</population>
          <units>Months</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Patient 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Toxicity</title>
        <description>Here is the number of participants with adverse events. For details of the adverse events, see the adverse event module.</description>
        <time_frame>21 months</time_frame>
        <population>Only recipients were monitored for adverse events.</population>
        <group_list>
          <group group_id="O1">
            <title>Recipients</title>
            <description>Vaccine and donor lymphocyte prep</description>
          </group>
        </group_list>
        <measure>
          <title>Toxicity</title>
          <description>Here is the number of participants with adverse events. For details of the adverse events, see the adverse event module.</description>
          <population>Only recipients were monitored for adverse events.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Graft Versus Host Disease (GVHD) Greater Than or Equal to Grade 3</title>
        <description>Acute Graft versus Host Disease (GVHD) was graded by the modified Glucksberg scale. 0 = no GVHD normal, 4 = severe GVHD.</description>
        <time_frame>28 days following completion of last vaccine and/or DLI (donor lymphocyte infusion) administration</time_frame>
        <population>Data for the frequency and severity of GVHD was captured as an endpoint for this trial. The donor arm is not included here because they were not evaluated for this outcome measure; recipients only.</population>
        <group_list>
          <group group_id="O1">
            <title>Recipients</title>
            <description>Vaccine and donor lymphocyte prep</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Graft Versus Host Disease (GVHD) Greater Than or Equal to Grade 3</title>
          <description>Acute Graft versus Host Disease (GVHD) was graded by the modified Glucksberg scale. 0 = no GVHD normal, 4 = severe GVHD.</description>
          <population>Data for the frequency and severity of GVHD was captured as an endpoint for this trial. The donor arm is not included here because they were not evaluated for this outcome measure; recipients only.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Immune Response</title>
        <description>Immune response was monitored by use of interferon gamma Enzyme-Linked Immunospot (ELISpot) and by delayed-type hypersensitivity (DTH) testing.</description>
        <time_frame>4 to 12 weeks</time_frame>
        <population>The donor arm is not included here because they were not evaluated for this outcome measure; recipients only.</population>
        <group_list>
          <group group_id="O1">
            <title>Recipients</title>
            <description>Period 1 - Vaccine and donor lymphocyte prep Period 2 - Vaccine and donor lymphocyte administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Immune Response</title>
          <description>Immune response was monitored by use of interferon gamma Enzyme-Linked Immunospot (ELISpot) and by delayed-type hypersensitivity (DTH) testing.</description>
          <population>The donor arm is not included here because they were not evaluated for this outcome measure; recipients only.</population>
          <units>Weeks</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patient 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not collected.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Wilm's Tumor 1 (WT1) Enzyme-Linked Immunospot (ELISpot)</title>
        <description>WT1 expression of the hematologic malignancy was confirmed by either having greater than 15% of malignant cells react with anti-WT1 by immunohistochemistry or by having a positive quantitative reverse transcription polymerase chain reaction (RT-PCR) of WT1 compared with a negative control.</description>
        <time_frame>48 to 72 hours after placement</time_frame>
        <population>The donor arm is not included here because they were not evaluated for this outcome measure; recipients only.</population>
        <group_list>
          <group group_id="O1">
            <title>Recipients</title>
            <description>Period 1 - Vaccine and donor lymphocyte prep Period 2 - Vaccine and donor lymphocyte administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Wilm's Tumor 1 (WT1) Enzyme-Linked Immunospot (ELISpot)</title>
          <description>WT1 expression of the hematologic malignancy was confirmed by either having greater than 15% of malignant cells react with anti-WT1 by immunohistochemistry or by having a positive quantitative reverse transcription polymerase chain reaction (RT-PCR) of WT1 compared with a negative control.</description>
          <population>The donor arm is not included here because they were not evaluated for this outcome measure; recipients only.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Wilm's Tumor (WT1) Delayed-type Hypersensitivity (DTH)</title>
        <description>WT1 expression of the hematologic malignancy was confirmed by either having greater than 15% of malignant cells react with anti-WT1 by immunohistochemistry or by having a positive quantitative reverse transcription polymerase chain reaction (RT-PCR) of WT1 compared with a negative control. DTH skin testing was performed using KLH and with a cocktail of WT1 peptides as 2 separate injections. Enzyme-Linked Immunospot (ELISpot) was performed against each peptide and was considered positive if results were at least 10 spots above background on at least 2 measurements. DTH was considered positive if there was at least .5cm induration 48 to 72 hours after placement.</description>
        <time_frame>48 to 72 hours after placement</time_frame>
        <population>The donor arm is not included here because they were not evaluated for this outcome measure; recipients only.</population>
        <group_list>
          <group group_id="O1">
            <title>Recipients</title>
            <description>Period 1 - Vaccine and donor lymphocyte prep Period 2 - Vaccine and donor lymphocyte administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Wilm's Tumor (WT1) Delayed-type Hypersensitivity (DTH)</title>
          <description>WT1 expression of the hematologic malignancy was confirmed by either having greater than 15% of malignant cells react with anti-WT1 by immunohistochemistry or by having a positive quantitative reverse transcription polymerase chain reaction (RT-PCR) of WT1 compared with a negative control. DTH skin testing was performed using KLH and with a cocktail of WT1 peptides as 2 separate injections. Enzyme-Linked Immunospot (ELISpot) was performed against each peptide and was considered positive if results were at least 10 spots above background on at least 2 measurements. DTH was considered positive if there was at least .5cm induration 48 to 72 hours after placement.</description>
          <population>The donor arm is not included here because they were not evaluated for this outcome measure; recipients only.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NA (Not available)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Keyhole Limpet Hemocyanin (KLH) Delayed-type Hypersensitivity (DTH)</title>
        <description>KLH is a neoantigen known to induce helper response was used concurrently as a vaccine adjuvant and control antigen. DTH skin testing was performed using KLH and with a cocktail of WT1 peptides as 2 separate injections. Enzyme-Linked Immunospot (ELISpot) was performed against each peptide and was considered positive if results were at least 10 spots above background on at least 2 measurements. DTH was considered positive if there was at least .5cm induration 48 to 72 hours after placement.</description>
        <time_frame>48 to 72 hours after placement</time_frame>
        <population>The donor arm is not included here because they were not evaluated for this outcome measure; recipients only.</population>
        <group_list>
          <group group_id="O1">
            <title>Recipients</title>
            <description>Period 1 - Vaccine and donor lymphocyte prep Period 2 - Vaccine and donor lymphocyte administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Keyhole Limpet Hemocyanin (KLH) Delayed-type Hypersensitivity (DTH)</title>
          <description>KLH is a neoantigen known to induce helper response was used concurrently as a vaccine adjuvant and control antigen. DTH skin testing was performed using KLH and with a cocktail of WT1 peptides as 2 separate injections. Enzyme-Linked Immunospot (ELISpot) was performed against each peptide and was considered positive if results were at least 10 spots above background on at least 2 measurements. DTH was considered positive if there was at least .5cm induration 48 to 72 hours after placement.</description>
          <population>The donor arm is not included here because they were not evaluated for this outcome measure; recipients only.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NA (Not available)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Progressive Disease</title>
        <description>Progressive disease is at least a 20% increase in the sum of the longest diameter of all target lesions (i.e. tumor response). Response criteria for acute leukemia's is worse marrow classification (i.e., M status) with at least a 50% increase in the percentage of marrow blasts, or no change in marrow classification (i.e., M status), but a 50% or greater increase in absolute peripheral blast count or extent of medullary disease</description>
        <time_frame>4 to12 weeks</time_frame>
        <population>The donor arm is not included here because they were not evaluated for this outcome measure; recipients only.</population>
        <group_list>
          <group group_id="O1">
            <title>Recipients</title>
            <description>Period 1 - Vaccine and donor lymphocyte prep Period 2 - Vaccine and donor lymphocyte administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Progressive Disease</title>
          <description>Progressive disease is at least a 20% increase in the sum of the longest diameter of all target lesions (i.e. tumor response). Response criteria for acute leukemia's is worse marrow classification (i.e., M status) with at least a 50% increase in the percentage of marrow blasts, or no change in marrow classification (i.e., M status), but a 50% or greater increase in absolute peripheral blast count or extent of medullary disease</description>
          <population>The donor arm is not included here because they were not evaluated for this outcome measure; recipients only.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>21 months</time_frame>
      <desc>Only recipients were monitored for adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Recipients</title>
          <description>Vaccine and donor lymphocyte prep</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Coagulation - Other, Specify - PT, prolonged</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Iron overload</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Platelets-low</sub_title>
                <counts group_id="E1" events="30" subjects_affected="5" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC) - low</sub_title>
                <counts group_id="E1" events="26" subjects_affected="4" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>PTT (partial thromboplastin time)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hemoglobin-low</sub_title>
                <counts group_id="E1" events="14" subjects_affected="4" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC) - low</sub_title>
                <counts group_id="E1" events="21" subjects_affected="4" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Supraventricular and nodal arrhythmia: sinus bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Supraventricular and nodal arrhythmia: sinus tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Ocular/Visual - Other, Specify - Eye drainage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pain: Eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Vision-blurred vision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pain: Abdomen NOS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Fever (in the absence of neutropenia, where neutropenia is defined as ANC &lt;1.0x10e9/L)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Rigors/chills</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Sweating (diaphoresis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pain:pain NOS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary/pancreas- Other, Specify - non-alcoholic Steatoheptits</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy/Immunology - Other, Specify - allergy to Sorbaview</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutriphils:lung (pneumonia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>Fever of unknown origin without clinically or microbiologically documented infection) (ANC &lt;1.0x10e9/L, fever &gt;=38.5 degrees C)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC:sinus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils:lung (pneumonia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils: upper airway NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>AST, SGOT (serum glutamic oxaloacetic transaminase) - high</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Glucose (serum -high (hyperglycemia)</sub_title>
                <counts group_id="E1" events="25" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Glucose, serum-low (hypoglycemia)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>GGT (gamma-Glutamyl transpeptidase)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Bicarbonate, serum low</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Albumin, serum low (hypoalbuminemia)</sub_title>
                <counts group_id="E1" events="19" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Magnesium, serum high (hypermagnesemia)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Magnesium, serum low (hypomagnesemia)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Triglyceride, serum high (hypertriglyceridemia)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Uric acid, serum high (hyperuricemia)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Potassium, serum-high (hyperkalemia)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Phosphate, serum low (hypophosphatemia)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>ALT, SGPT (serum glutamic pyruvic transaminase) - high</sub_title>
                <counts group_id="E1" events="12" subjects_affected="3" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Bilirubin (hyperbilirubinemia)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Calcium, serum-low (hypocalcemia)</sub_title>
                <counts group_id="E1" events="18" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Cholesterol, serum-high (hypercholesteremia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Potassium, serum-low (hypokalemia)</sub_title>
                <counts group_id="E1" events="9" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Sodium, serum-high (hypernatremia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Sodium, serum-low (hyponatremia)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain:Joint</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pain: neck</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pain:muscle</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Pain: Head/Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Mood alteration:anxiety</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary frequency/urgency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis (including sneezing, nasal stuffiness, postnasal drip)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hemorrhage, pulmonary/upper respiratory: Nose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pain: chest wall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pain: throat/pharynx/larynx</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bruising (in absence of Grade 3 or 4 thrombocytopenia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" events="11" subjects_affected="4" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Striae</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pruritis/itching</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Terry Fry</name_or_title>
      <organization>National Cancer Institute</organization>
      <phone>301-402-0215</phone>
      <email>fryt@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

